About Cerexa
Cerexa is a company based in Alameda (United States) founded in 2005 was acquired by Forest Laboratories in December 2006.. The company has 2,961 employees as of December 31, 2021. Cerexa operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
- Headquarter Alameda, United States
- Employees 2961 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Abbvie Deutschland Gmbh & Co. Kg
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
- Investors
-
Employee Count
2961
as on Dec 31, 2021
-
Acquired by
Forest Laboratories
(Dec 13, 2006)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Cerexa
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Cerexa
Cerexa has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Forest Laboratories. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pharmaceutical formulations are developed and marketed by Forest Laboratories.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Cerexa
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Cerexa
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cerexa Comparisons
Competitors of Cerexa
Cerexa operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| domain | founded_year | HQ Location |
Pleuromutilin antibiotics are developed for MDR infections.
|
|
| domain | founded_year | HQ Location |
Developer of bacterial ribosome-targeting drugs for MDR infections
|
|
| domain | founded_year | HQ Location |
Developer of antibiotics for MDR infections
|
|
| domain | founded_year | HQ Location |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
|
| domain | founded_year | HQ Location |
Pharmaceuticals for acute care bacterial infections are developed and commercialized.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Cerexa
When was Cerexa founded?
Cerexa was founded in 2005.
Where is Cerexa located?
Cerexa is headquartered in Alameda, United States. It is registered at Alameda, California, United States.
How many employees does Cerexa have?
As of Dec 31, 2021, the latest employee count at Cerexa is 2,961.
What does Cerexa do?
Cerexa is focused on the development of hospital-based anti-infective therapies to infections that are resistant to antibiotics. Its product portfolio includes Ceftaroline Acetate, a hospital-based cephalosporin antibiotic that exhibits bactericidal activity against the strains of Gram- positive bacteria, including MRSA (methicillin-resistant Staphylococcus aureus); ME1036, a broad-spectrum parenteral carbapenem against both aerobic and anaerobic Gram-positive and Gram-negative bacteria, including common drug-resistant pathogens. On December 13, 2006 Forest Laboratories acquired Cerexa for a total of 480M.
Who are the top competitors of Cerexa?
Cerexa's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Who are Cerexa's investors?
Cerexa has 1 investor. Key investors include Forest Laboratories.